Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an inorganic compound
Patent
1999-03-19
2000-06-13
Jones, Dameron
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an inorganic compound
424 111, 424649, A61K 5100, A61M 3614
Patent
active
060746262
ABSTRACT:
Background: Between 1991 and 1997 sixty-seven patients with non-resectable hepatoma were treated with hepatic artery infusions (HAI) of cisplatinum. Patients were divided into groups for analysis based on alpha-fetoprotein elevation (AFP+) or no elevation (AFP-), hepatitis B/C status, the presence or absence of extra-hepatic metastases and primary treatment at our facility or initial therapy elsewhere.
Methods: Forty-four patients received an initial course of 21-24 Gy whole liver external radiation with cisplatinum 50 mg/m.sup.2 IV on days 1 and 8 of radiation. Twenty-three patients did not receive external radiation and received HAI cisplatinum only. All patients were then treated with HAI cisplatinum at 50 mg/m.sup.2 on a monthly basis. The rationale for the advantage to HAI cisplatinum was evaluated by giving a tracer dose of radioactive .sup.195m cisplatinum for quantitative determinations by the intra-arterial route in six patients.
Results: A 50% overall response rate was seen, as judged by a 50% reduction in tumor diameter or a 50% reduction in AFP titer. Monthly HAI cisplatinum at 50 mg/m.sup.2 was well tolerated and could be repeated indefinitely without significant toxicity. Median survival for primarily treated non-resectable hepatomas AFP(+) and AFP(-) was 12 months and 17.5 months, respectively. Statistical analysis of all patients AFP(+) versus AFP(-) revealed a log rank statistical difference in survival of P=0.007. For patients with hepatitis B or C median survival was 10.7 months regardless of AFP status. Radioactive cisplatinum given by hepatic arterial infusion provided 34-55% tumor uptake of cisplatinum.
Conclusions: Intra-arterial delivery of 50 mg/m.sup.2 cisplatinum on a monthly basis is a well-tolerated regimen for patients with non-resectable hepatoma. These data suggest a baseline chemotherapy regimen against which randomized trials could be evaluated. Further, the selective uptake of cisplatinum delivered intra-arterially suggests other selective intra-arterial protocols would be of use in regional cancers treated with cisplatinum.
Keywords: Hepatoma, hepatocellular, carcinoma, cisplatin, cisplatinum, .sup.195m cisplatinum, radioisotopes, intra-arterial.
REFERENCES:
patent: 4322391 (1982-03-01), Kaplan et al.
patent: 4451447 (1984-05-01), Kaplan et al.
patent: 4536386 (1985-08-01), Keenan
patent: 4889724 (1989-12-01), Kasan et al.
patent: 5340565 (1994-08-01), Prio
patent: 5484612 (1996-01-01), Brown
patent: 5844001 (1998-12-01), McClay et al.
Dox et al, The Harper Collins Illustrated Medical Dictionary, pp. 12, 27, & 360, 1993.
The Merck Index, pp. 361 & 1196, 1989.
Jones Dameron
Molecular Radiation Management, Inc.
LandOfFree
Radioactive cisplatin in the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radioactive cisplatin in the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radioactive cisplatin in the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2066127